This study reported the long-term effectiveness and safety of encorafenib (Braftovi) alone or in combination with binimetinib (Mektovi) or vemurafenib (Zelboraf) alone in patients with BRAF-mutated advanced melanoma. The data showed that the encorafenib plus binimetinib combination lead to long-term effectiveness and no new safety issues in these patients.

This study evaluated the effectiveness and safety of immune checkpoint inhibitors (ICIs) either alone or in combination for the treatment of patients with advanced melanoma. The data showed that nivolumab (Opdivo) and ipilimumab (Yervoy) combination therapy was more effective than nivolumab or ipilimumab alone for the treatment of these patients.

This study evaluated which sequence of treatment should be given first - immunotherapy or targeted therapy - for the most clinical benefit in patients with BRAF-mutated metastatic melanoma. The data showed that immunotherapy followed by targeted therapy significantly improved survival outcomes in these patients.

This study evaluated the effectiveness and safety of different treatments given after surgery in patients with advanced melanoma. The data showed that nivolumab (Opdivo) plus ipilimumab (Yervoy) was the best treatment regimen in significantly improving overall survival and survival without cancer worsening in these patients.

This study investigated the effectiveness and safety of fractionated stereotactic radiation therapy (FSRT) for patients with small and moderate-sized brain metastases (BM). The data showed that FSRT was safe and effective in patients with BM of any size with excellent local control.

The study aimed to evaluate the safety and effectiveness of an immunomodulatory IDO/PD-L1 targeting peptide vaccine (IO102/IO103) combined with nivolumab (Opdivo) in patients with metastatic melanoma (MM). The study concluded that the IO102/IO103 vaccine combined with nivolumab is safe and effective in these patients.

This study evaluated the effectiveness and safety of immune checkpoint inhibitors (ICIs) in combination with palliative (treatment to relieve pain) radiotherapy (pRT) for the treatment of patients with advanced melanoma. The data showed that the addition of pRT to ICIs is effective and safe in these patients.

This study evaluated the effectiveness and safety of sequential administration of high dose aldesleukin (Interleukin-2; Proleukin) and ipilimumab (Yervoy) in patients with metastatic melanoma. The data showed that high dose aldesleukin and ipilimumab were effective and safe when administered sequentially in these patients.

This study investigated the optimal doses of hypofractionated stereotactic radiation therapy (HSRT) for patients with brain metastases (BM). The data showed that a HSRT dose of 30 Gy or higher delivered in 5 daily fractions was safe and effective in these patients.

This study evaluated the effectiveness and safety of triple combination therapy with immune and targeted therapies in patients with stage III-IV melanoma. The data showed that triple combination therapy was associated with increased survival benefits with manageable side effects for these patients.